News Release

Nature Article Cites NuGel™-HemogloBind™ in Study of Reprogramming Tumour-associated Macrophages

MONMOUTH JUNCTION, NJ , July 17, 2023 -- Biotech Support Group reports on a journal article describing the simplicity and efficiency of NuGel™ HemogloBind™, to remove Hemoglobin interference, in a LC-MS amino acid analysis of mouse tumor interstitial fluid.

The citation is:

Zhang, X., Li, S., Malik, I. et al. Reprogramming tumour-associated macrophages to outcompete cancer cells. Nature (2023). https://doi.org/10.1038/s41586-023-06256-5

Tumours are metabolically active and are populated by stroma cells, but how environmental factors affect cancer cell competition remains largely unknown. The study evaluated how tumour-associated macrophages (TAMs) can be dietarily or genetically reprogrammed to outcompete MYC-overexpressing cancer cells. In a mouse model of breast cancer, MYC overexpression resulted in an mTORC1-dependent ‘winner’ cancer cell state. To measure the amino acid content by LC-MS from tumor interstitial fluid, the article states “Samples were brought through a NuGel-HemogloBind (Biotech Support Group) prep prior to extraction to remedy the levels of haemolysis present. Twenty microliters of sample was added to a microfuge tube and mixed with 200 µl of HemogloBind Binding Buffer…The total volume (220 µl) was then transferred to a Spin-filter tube that was pre-conditioned with 50 mg NuGel-HemogloBind beads. The spin-filter tubes were then vortexed again at room temperature for 10 min before centrifuging at 8,000g for 4 min.” The article concludes noncanonical engulfment-medieated Rag GTPase-independent mTORC1 signalling in TAMs controls competition between TAMs and cancer cells, which defines a novel innate immune tumour suppression pathway that could be targeted for cancer therapy.


“Here is another example of the versatility of NuGel™ HemogloBind™, as it is used here to clear Hemoglobin interference from tumor interstitial fluid in LC-MS amino acid analysis. This also demonstrates another key feature of our products. As they are not based on immuno-affinity, all of our products can be used for any species” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Click here for more information on NuGel™ HemogloBind™

Click here for more information on all of our Hemoglobin Removal products

Keywords: tumor interstitial fluid , tumour-associated macrophages , amino acid analysis, NuGel™ HemogloBind™, hemoglobin removal

About Biotech Support Group LLC

Converging with technological disruptions forthcoming in healthcare, Biotech Support Group continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, For more information, go to http://www.biotechsupportgroup.com.

For Business Development , contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com